Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$36.28 - $75.29 $361,856 - $750,942
-9,974 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$69.73 - $142.9 $212,467 - $435,416
3,047 Added 43.99%
9,974 $735,000
Q4 2021

Feb 11, 2022

BUY
$134.56 - $217.97 $12,514 - $20,271
93 Added 1.36%
6,927 $991,000
Q3 2021

Nov 12, 2021

SELL
$177.8 - $270.58 $672,617 - $1.02 Million
-3,783 Reduced 35.63%
6,834 $1.42 Million
Q2 2021

Aug 13, 2021

BUY
$121.0 - $257.67 $661,023 - $1.41 Million
5,463 Added 106.0%
10,617 $2.25 Million
Q1 2021

May 14, 2021

SELL
$112.98 - $319.93 $42,141 - $119,333
-373 Reduced 6.75%
5,154 $934,000
Q4 2020

Feb 12, 2021

BUY
$78.74 - $139.5 $435,195 - $771,016
5,527 New
5,527 $616,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $704M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Parkwood LLC Portfolio

Follow Parkwood LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkwood LLC with notifications on news.